Advertisement

Immuntherapie des metastasierten Nierenzellkarzinoms mit rekombinantem Interferon-γ

  • G. Gastl
  • N. H. Bander
  • J. Frick
  • C. Huber
  • W. Aulitzky
Conference paper

Zusammenfassung

Das Nierenzellkarzinom (NZK) ist ein Tumor, der gegen Chemotherapie resistent ist. Die berichtete durchschnittliche Überlebensrate bei Patienten mit metastatischer Krankheit beträgt ungefähr 10 Monate (Maldazys u. de Kernion 1986). Vor kurzem wurden jedoch experimentelle und klinische Beweise dafür erbracht, daß das NZK gegenüber verschiedenen Formen der Immuntherapie, einschließlich der IL-2-Behandlung mit oder ohne adopti-vem Transfer von lymphokinaktivierten Killerzellen (LAK-Zellen) oder Interferon (IFN)-γ verhältnismäßig sensibel ist (Graham 1989). In diesem Bericht präsentieren wir vorklinische Daten und revidieren unsere jüngsten Erfahrungen mit der Entwicklung einer effektiven Immuntherapie für Patienten mit fortgeschrittenem NZK unter Verwendung von IFN-y.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aulitzky W, Gastl G, Aulitzky WE et al. (1987) Interferon-gamma for the treatment of metastatic renal cancer: Dose-dependent stimulation and down-regulation of soluble beta-2 microglobulin and neopterin responses. Immunobiology 176: 85–89PubMedCrossRefGoogle Scholar
  2. Aulitzky W, Gastl G, Aulitzky WE et al. (1989) Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. J Clin Oncol 7: 1875–1884PubMedGoogle Scholar
  3. Aulitzky WE, Aulitzky W, Frick J et al. (1990) Treatment of cancer patients with recombinant interferon-gamma induces release of endogenous tumor necrosis factoralpha. Immunobiology 180: 385–394PubMedCrossRefGoogle Scholar
  4. Aulitzky WE, Grosse-Wilde H, Westhoff U et al. (1991) Enhanced serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon-gamma (IFN-gamma). Clin Exp Immunol 86: 236–239PubMedCrossRefGoogle Scholar
  5. Bander NH (1989) Monoclonal antibodies to renal cancer antigens. Semin Urol 7: 264–270PubMedGoogle Scholar
  6. Belldegrun A, Muul LM, Rosenberg SA (1988) Interleukin-2 expanded tumor-infiltrating lymphocytes in human renal cancer: isolation, characterization and anti-tumor activity. Cancer Res 48: 206–210PubMedGoogle Scholar
  7. Boon T (1992) Toward a genetic analysis of tumor rejection antigens. Adv Cancer Res 58: 177–210PubMedCrossRefGoogle Scholar
  8. Cordon-Cardo C, Fuks Z, Drobnjak Z, Moreno C, Eisenbach L, Feldman M (1991)Google Scholar
  9. Expression of HLA-A,B,C antigens on primary and metastatic tumor cell populations of human carcinomas. Cancer Res 51: 6372–6380Google Scholar
  10. de Riese W, Allhoff E, Kirchner H, Stief CG, Atzpodien J, Maschek H, Jonas U (1991) Complete spontaneous regression in metastatic renal cell carcinoma — an update and review. World J Urol 9: 184–191Google Scholar
  11. Elliot BE, Carlow DA, Rodricks A, Wade A (1989) Perspectives on the role of MHC antigens in normal and malignant cell development. Adv Cancer Res 53: 181–245CrossRefGoogle Scholar
  12. Garnick MB, Reich SD, Maxwell (1988) Phase I/II study of recombinant interferon-gamma in advanced renal cell carcinoma. J Urol 139: 251–255PubMedGoogle Scholar
  13. Gastl G, Huber C (1988) The biology of interferon actions. Blut 56: 193–199PubMedCrossRefGoogle Scholar
  14. Gastl G, Marth C, Leiter E et al. (1985) Effects of recombinant alpha-2 arg-interferon and gamma-interferon on human breast cancer cell lines: Dissociation of antiproliferative activity and induction of HLA-DR expression. Cancer Res 45: 2957–2961PubMedGoogle Scholar
  15. Graham SD (1989) Immunotherapy of renal cell carcinoma. Semin Urol 7: 215–227PubMedGoogle Scholar
  16. Grups JW, Frohmueller HGW (1989) Cyclic interferon-gamma treatment of patients with metastatic renal carcinoma. Br J Urol 64: 218–220PubMedCrossRefGoogle Scholar
  17. Heicappel R, Ackermann R (1991) Current strategies for immunotherapy of renal cell carcinoma. World J Urol 9: 204–209CrossRefGoogle Scholar
  18. Levin I, Kuperman O, Goldstein J et al. (1991) Cellular β-2 microglobulin expression as a prognostic indicator in renal cell carcinoma. Acta Oncol 30: 941–945PubMedCrossRefGoogle Scholar
  19. Maldazys JD, de Kernion JB (1986) Prognostic factors in metastatic renal cell carcinoma. J Urol 136: 376–379PubMedGoogle Scholar
  20. Maluish AE, Urba WJ, Longo DL et al. (1988) The determination of an immunologically active dose of interferon-gamma in patients with melanoma. J Clin Oncol 6: 434–441PubMedGoogle Scholar
  21. Osband ME, Ross S (1990) Problems in the investigational study and clinical use of cancer immunotherapy. Immunol Today 11: 24–31CrossRefGoogle Scholar
  22. Otto U, Schneider A, Denkhaus H, Conrad S (1988) Die Behandlung des metastasierenden Nierenkarzinoms mit rekombinantem alpha-2- oder gamma-interferon. Onkologie 11: 185–191PubMedCrossRefGoogle Scholar
  23. Quesada JR, Kurzrock R, Sherwin SA (1987) Phase II studies of recombinant interferon- gamma in metastatic renal cell carcinoma. J Biol Respir Mod 6: 20–27Google Scholar
  24. Rinehart JJ, Malspeis I, Young D (1986) Phase I/II trial of human recombinant interferon gamma in advanced renal cell carcinoma. J Biol Respir Mod 5: 300–308Google Scholar
  25. Takaku H, Kumamoto Y, Koiso K et al. (1987) Phase II study of recombinant human interferon-gamma (S-6810) on renal cell carcinoma. Summary of two collaborative studies. Cancer 60: 929–933CrossRefGoogle Scholar
  26. Trinchieri G, Perussia B (1985) Immune interferon: A pleiotropic lymphokine with multiple effects. Immunol Today 6: 131–136CrossRefGoogle Scholar
  27. Weiner LM, Steplewski Z, Koprowski H, Litwin S, Comis RL (1988) Divergent dose-related effects of gamma-interferon therapy on in vitro antibody-dependent cellular and nonspecific cytotoxicity by human peripheral blood monocytes. Cancer Res 48: 1042–1049PubMedGoogle Scholar
  28. Zinkernagel RM, Döherty PC (1979) MHC cytotoxic T cells: Studies on the biological role of polymorphic major transplantation antigens determining T cell restriction: Specificity, function and responsiveness. Adv Immunol 27: 51–78PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • G. Gastl
  • N. H. Bander
  • J. Frick
  • C. Huber
  • W. Aulitzky

There are no affiliations available

Personalised recommendations